HC Wainwright Issues Pessimistic Forecast for Invivyd (NASDAQ:IVVD) Stock Price

Invivyd (NASDAQ:IVVD) had its price target decreased by investment analysts at HC Wainwright from $15.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th.

Invivyd Trading Up 3.7 %

Shares of NASDAQ:IVVD opened at $0.77 on Wednesday. Invivyd has a 1-year low of $0.72 and a 1-year high of $5.20. The stock has a market capitalization of $91.79 million, a P/E ratio of -0.39 and a beta of 0.65. The business has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.26.

Institutional Investors Weigh In On Invivyd

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its stake in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the last quarter. State Street Corp increased its stake in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Invivyd during the third quarter worth approximately $27,000. Cubist Systematic Strategies LLC lifted its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Invivyd in the 2nd quarter valued at $115,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.